ClinicalTrials.gg
CompletedNCT00756678Updated Oct 31, 2011Results posted

Efficacy and Acceptability of Two Lubricant Eye Drops

A Phase 4 interventional study of Lubricant Eye Drops (Optive™) and Lubricating Eye Drops (blink® Tears) in Dry Eye Syndromes, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-31.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Lubricant Eye Drops in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Lubricant Eye Drops · Dry Eye Syndromes.

Enrollment
3rd of 10
51 · median 39
Started
2008
the only one that year
Phase 4
5 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
1 of 10
Allergan

Among the 10 studies testing Lubricant Eye Drops in Dry Eye Syndromes, this one is the 3rd largest by enrollment, is the only one that started in 2008, is one of 5 in phase 4, and was the 2nd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 10 studies testing Lubricant Eye Drops in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About Lubricant Eye Drops

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Lubricant Eye Drops in Dry Eye Syndromes, or all of them as a file.
02

Study summary

Efficacy and acceptability of two new artificial tears following two weeks of treatment in patients with dry eye. Patients will be randomized to 1 of 2 treatments for 7 days then crossover to the alternate treatment for 7 days.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female
  • At least 18 years of age
  • Current use of artificial tears

Exclusion criteria

Exclusion Criteria:

  • Any uncontrolled systemic disease
  • Pregnancy or planning a pregnancy
  • Contact lens wear
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    1

    Carboxymethylcellulose and Glycerin

    Drug: Lubricant Eye Drops (Optive™)

  • Active comparator
    2

    Polyethylene glycol 400

    Drug: Lubricating Eye Drops (blink® Tears)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Frequency of Eye Drop Use Over 1 Week

    Mean frequency of eye drop use per day per patient during the cross-over period over 1 week. Eye drop use was captured on a daily tear diary that the patients completed. The greater the frequency of use, the more eye drops were required to manage the patient's dry eye symptoms.

    Time frame: 1 week

Secondary outcomes

  1. Change From Baseline in Dry Eye Disease Comfort Assessment Score on Day 16

    Mean change from baseline in Dry Eye Disease Comfort Assessment Score at Day 16. The Dry Eye Disease Comfort Assessment consists of one question asking the patient to rate their current overall discomfort from their dry eye symptoms on a scale of 0 to 10 (0 equals No Discomfort; 10 equals Intolerable). The greater the negative number change from baseline, the greater the improvement in comfort.

    Time frame: Baseline, Day 16

  2. Percentage of Positive Patient Responses to Subject Acceptability Questionnaire on Day 16

    Percentage of patients who responded "Strongly Agree" and "Agree" to Subject Acceptability Questionnaire Question 1: Overall Liked. The Subject Acceptability Questionnaire consists of 11 multiple choice questions assessing how the patients feel about the eye drops received. The 5 possible responses to the questionnaire are "Strongly Agree", "Agree", "Neither Agree or Disagree", "Disagree" and "Strongly Disagree".

    Time frame: Day 16

  3. Number of Patients With Positive Responses to Subject Preference Questionnaire on Day 16

    Number of patients who marked that either Week 1 study product was more soothing or Week 2 study product was more soothing to the Overall Comfort Preference Questionnaire on Day 16 of the cross-over period. The Subject Preference Questionnaire consists of 4 questions related to comfort, soothing, blurring and purchase preference comparing treatments received during Week 1 versus Week 2.

    Time frame: Day 16

07

Results

Posted Oct 31, 2011

Participant flow

Participant flow — Overall Study
MilestoneAll Patients
Started51
Completed50
Not completed1

Outcome measures

PrimaryMean Frequency of Eye Drop Use Over 1 Week

Mean frequency of eye drop use per day per patient during the cross-over period over 1 week. Eye drop use was captured on a daily tear diary that the patients completed. The greater the frequency of use, the more eye drops were required to manage the patient's dry eye symptoms.

Time frame:
1 week
Reported as:
Mean · Use per day
Mean Frequency of Eye Drop Use Over 1 Week
Use per dayLubricant Eye Drops (Optive™)Lubricant Eye Drops (Blink® Tears)
Mean Frequency of Eye Drop Use Over 1 Week1.76 ± 0.899211.66 ± 0.94459
SecondaryChange From Baseline in Dry Eye Disease Comfort Assessment Score on Day 16

Mean change from baseline in Dry Eye Disease Comfort Assessment Score at Day 16. The Dry Eye Disease Comfort Assessment consists of one question asking the patient to rate their current overall discomfort from their dry eye symptoms on a scale of 0 to 10 (0 equals No Discomfort; 10 equals Intolerable). The greater the negative number change from baseline, the greater the improvement in comfort.

Time frame:
Baseline, Day 16
Reported as:
Mean · Scores on a scale
Change From Baseline in Dry Eye Disease Comfort Assessment Score on Day 16
Scores on a scaleLubricant Eye Drops (Optive™)Lubricant Eye Drops (Blink® Tears)
Baseline4.65 ± 1.8434.62 ± 1.839
Day 16-1.41 ± 2.010-1.47 ± 1.905
SecondaryPercentage of Positive Patient Responses to Subject Acceptability Questionnaire on Day 16

Percentage of patients who responded "Strongly Agree" and "Agree" to Subject Acceptability Questionnaire Question 1: Overall Liked. The Subject Acceptability Questionnaire consists of 11 multiple choice questions assessing how the patients feel about the eye drops received. The 5 possible responses to the questionnaire are "Strongly Agree", "Agree", "Neither Agree or Disagree", "Disagree" and "Strongly Disagree".

Time frame:
Day 16
Reported as:
Number · Percentage of Patients
Percentage of Positive Patient Responses to Subject Acceptability Questionnaire on Day 16
Percentage of PatientsLubricant Eye Drops (Optive™)Lubricant Eye Drops (Blink® Tears)
Percentage of Positive Patient Responses to Subject Acceptability Questionnaire on Day 168678
SecondaryNumber of Patients With Positive Responses to Subject Preference Questionnaire on Day 16

Number of patients who marked that either Week 1 study product was more soothing or Week 2 study product was more soothing to the Overall Comfort Preference Questionnaire on Day 16 of the cross-over period. The Subject Preference Questionnaire consists of 4 questions related to comfort, soothing, blurring and purchase preference comparing treatments received during Week 1 versus Week 2.

Time frame:
Day 16
Reported as:
Number · Number of patients
Number of Patients With Positive Responses to Subject Preference Questionnaire on Day 16
Number of patientsLubricant Eye Drops (Optive™)Lubricant Eye Drops (Blink® Tears)
Number of Patients With Positive Responses to Subject Preference Questionnaire on Day 161622

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Patients—0/51 (0%)0/51 (0%)

Baseline characteristics

Age, Customized
Age, Customized(participants)All Patients
<=40 years22
Between 40 and 65 years24
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)All Patients
Female37
Male14
08

Study locations

1 site
  • Chevy Chase, Maryland, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2008
First posted
Sep 22, 2008
Start
Sep 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Oct 31, 2011
Last update
Oct 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00756678
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Sep 22, 2008
Start date
Sep 2008
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Oct 31, 2011
Last update
Oct 31, 2011

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lubricant Eye Drops

Start the discussion